CTOs on the Move

Minerva Neurosciences

www.minervaneurosciences.com

 
Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Leveraging extensive domain expertise, we have identified and acquired or in-licensed a portfolio of development-stage proprietary compounds with what we believe are innovative mechanisms of action. Our executive management team includes globally recognized specialists in central nervous system diseases addressing significant unmet medical needs. Our strategy is based on the following key principles: • Develop differentiated products based on biological and clinical ...
  • Number of Employees: 25-100
  • Annual Revenue: $100-250 Million

Executives

Name Title Contact Details

Similar Companies

Applied Proteomics

Applied Proteomics Inc. is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems.

Cardiome Pharma

Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genosco

Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Home Advantage

Home Advantage is a Herndon, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inform Genomics

Inform Genomics, Inc, is a privately held company that utilizes a proprietary technology platform to discover and develop genomic-based, precision medicine products that are designed to predict, with a high degree of accuracy, clinically important outcomes that assist physicians and their patients in making individualized medical decisions. Its lead development program is in oncology supportive care, with two major products currently in development--OnPART™ and HSCT/Mucositis™--designed not only to predict a patient's risk for developing common chemotherapy-related side effects, but also to assess a patient's willingness to tolerate those side effects. The Company's novel, IP-protected technology platform capitalizes on big data storage/memory and sophisticated cloud computing technologies. It consists of proprietary Bayesian networks and other advanced bioinformatic analytics combined with validated patient assessment tools. The Company's analytics discover interactions of genes and single nucleotide polymorphisms (SNPs) that can predict clinical outcomes. Inform Genomics' goal is to be a trusted partner to health care practitioners so that they, together with their patients, can make optimal health care choices based on an individual patient's needs and values.